Drug Profile
Rodatristat - Sumitomo Pharma America
Alternative Names: KAR-5417Latest Information Update: 18 Jul 2023
Price :
$50
*
At a glance
- Originator Karos Pharmaceuticals
- Developer Sumitomo Pharma America
- Class Antihypertensives; Aza compounds; Pyrimidines; Small molecules; Spiro compounds
- Mechanism of Action Serotonin modulators; Tryptophan hydroxylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Pulmonary arterial hypertension